Protection Against Respiratory Syncytial Virus by Inactivated Influenza Virus Carrying a Fusion Protein Neutralizing Epitope in a Chimeric Hemagglutinin

Overview

Journal Nanomedicine

Publisher Elsevier

Specialties Biomedical Engineering
Biotechnology

Date 2015 Dec 15

PMID 26656630

Citations 5

Authors

Yu-Na Lee

Hye Suk Hwang

Min-Chul Kim

Young-Tae Lee

Yu-Jin Kim

F Eun-Hyung Lee

Sang-Moo Kang

Affiliations

Soon will be listed here.

Abstract

From The Clinical Editor: Respiratory syncytial virus (RSV) is a major cause of respiratory tract illness and morbidity in children. Hence, there is a need to develop an effective vaccine against this virus. In this article, the authors engineered chimeric influenza virus to express RSV neutralizing epitopes. The positive findings in in-vivo experiments provide a beginning for future clinical trials and perhaps eventual product realization.

Citing Articles

Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus.

Durie I, Tehrani Z, Karaaslan E, Sorvillo T, McGuire J, Golden J Nat Commun. 2022; 13(1):7298.

PMID: 36435827 PMC: 9701186. DOI: 10.1038/s41467-022-34923-0.

Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.

Park B, Subbiah J, Kim K, Kwon Y, Oh J, Kim M Virology. 2021; 566:143-152.

PMID: 34929590 PMC: 8903020. DOI: 10.1016/j.virol.2021.12.003.

Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin.

Park B, Kim K, Kotomina T, Kim M, Kwon Y, Jeeva S Sci Rep. 2021; 11(1):4151.

PMID: 33603072 PMC: 7893060. DOI: 10.1038/s41598-021-83704-0.

Recombinant Live Attenuated Influenza Virus Expressing Conserved G-Protein Domain in a Chimeric Hemagglutinin Molecule Induces G-Specific Antibodies and Confers Protection against Respiratory Syncytial Virus.

Jung Y, Lee Y, Kim K, Lee Y, Jeeva S, Park B Vaccines (Basel). 2020; 8(4).

PMID: 33271920 PMC: 7711863. DOI: 10.3390/vaccines8040716.

Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Kim K, Jung Y, Lee Y, Park B, Oh J, Lee Y Virology. 2020; 550:51-60.

PMID: 32882637 PMC: 7554235. DOI: 10.1016/j.virol.2020.08.003.

References

Reed J, Brewah Y, Delaney T, Welliver T, Burwell T, Benjamin E . Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J Infect Dis. 2008; 198(12):1783-93. DOI: 10.1086/593173. View

Kim H, Canchola J, BRANDT C, Pyles G, Chanock R, Jensen K . Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969; 89(4):422-34. DOI: 10.1093/oxfordjournals.aje.a120955. View

Murawski M, McGinnes L, Finberg R, Kurt-Jones E, Massare M, Smith G . Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol. 2009; 84(2):1110-23. PMC: 2798376. DOI: 10.1128/JVI.01709-09. View

Karron R, Wright P, Belshe R, Thumar B, Casey R, Newman F . Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis. 2005; 191(7):1093-104. DOI: 10.1086/427813. View

Victor S, Watanabe S, Katsura H, Ozawa M, Kawaoka Y . A replication-incompetent PB2-knockout influenza A virus vaccine vector. J Virol. 2012; 86(8):4123-8. PMC: 3318628. DOI: 10.1128/JVI.06232-11. View

Caton A, Brownlee G, Yewdell J, GERHARD W . The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell. 1982; 31(2 Pt 1):417-27. DOI: 10.1016/0092-8674(82)90135-0. View

Wright P, Karron R, Madhi S, Treanor J, King J, OShea A . The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis. 2006; 193(4):573-81. DOI: 10.1086/499600. View

Lee Y, Hwang H, Kim M, Lee Y, Cho M, Kwon Y . Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease. Virology. 2015; 476:217-225. PMC: 4323758. DOI: 10.1016/j.virol.2014.12.004. View

Cox R, Hovden A, Brokstad K, Szyszko E, Madhun A, Haaheim L . The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice. Vaccine. 2006; 24(44-46):6585-7. DOI: 10.1016/j.vaccine.2006.05.040. View

10.

Bian C, Liu S, Liu N, Zhang G, Xing L, Song Y . Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice. Antiviral Res. 2014; 104:110-7. DOI: 10.1016/j.antiviral.2014.01.022. View

11.

Castilow E, Varga S . Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol. 2008; 3(5):445-454. PMC: 2593094. DOI: 10.2217/17460794.3.5.445. View

12.

Castilow E, Meyerholz D, Varga S . IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J Immunol. 2008; 180(4):2376-84. DOI: 10.4049/jimmunol.180.4.2376. View

13.

Kim Y, Quan F, Compans R, Kang S, Prausnitz M . Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release. 2009; 142(2):187-95. PMC: 2823933. DOI: 10.1016/j.jconrel.2009.10.013. View

14.

Murphy B, Sotnikov A, Lawrence L, Banks S, Prince G . Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine. 1990; 8(5):497-502. DOI: 10.1016/0264-410x(90)90253-i. View

15.

Hoffmann E, Krauss S, Perez D, Webby R, Webster R . Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine. 2002; 20(25-26):3165-70. DOI: 10.1016/s0264-410x(02)00268-2. View

16.

Ferko B, Stasakova J, Sereinig S, Romanova J, Katinger D, Niebler B . Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. J Virol. 2001; 75(19):8899-908. PMC: 114458. DOI: 10.1128/JVI.75.19.8899-8908.2001. View

17.

Chin J, MAGOFFIN R, Shearer L, SCHIEBLE J, LENNETTE E . Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969; 89(4):449-63. DOI: 10.1093/oxfordjournals.aje.a120957. View

18.

Graham B . Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev. 2011; 239(1):149-66. PMC: 3023887. DOI: 10.1111/j.1600-065X.2010.00972.x. View

19.

Shirey K, Lai W, Pletneva L, Karp C, Divanovic S, Blanco J . Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology. Mucosal Immunol. 2013; 7(3):549-57. PMC: 3965659. DOI: 10.1038/mi.2013.71. View

20.

Ehlenfield D, Cameron K, Welliver R . Eosinophilia at the time of respiratory syncytial virus bronchiolitis predicts childhood reactive airway disease. Pediatrics. 2000; 105(1 Pt 1):79-83. DOI: 10.1542/peds.105.1.79. View